Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

Nobuyuki Takayama, Norihide Sato, Stephen G. O'Brien, Yasuo Ikeda, Shin Ichiro Okamoto

Research output: Contribution to journalArticle

110 Citations (Scopus)


A 32-year-old woman with relapsed Philadelphia chromosome-positive acute lymphoblastic leukaemia was treated with imatinib mesylate (formerly STI571), a selective inhibitor of BCR/ABL tyrosine kinase. Although the initial marrow response was good and stably maintained, she subsequently relapsed with extensive infiltration of leukaemic cells into the central nervous system (CNS). After controlling her CNS disease with additional intrathecal chemotherapy, we measured the concentration of imatinib in cerebrospinal fluid (CSF) and blood simultaneously. The concentration of imatinib in CSF was about 92-fold lower than that in blood. These results suggest that imatinib poorly penetrates the blood-brain barrier and has limited activity against CNS leukaemia.

Original languageEnglish
Pages (from-to)106-108
Number of pages3
JournalBritish Journal of Haematology
Issue number1
Publication statusPublished - 2002 Oct 29



  • Acute lymphoblastic leukaemia
  • Blood-brain barrier
  • Central nervous system
  • Imatinib mesylate
  • Philadelphia chromosome

ASJC Scopus subject areas

  • Hematology

Cite this